Figure 5. JAK1 S646P mutation exhibits increased sensitivity to JAK1/2 inhibitor.

(A) Transiently transfected HEK293V cells were treated with increasing concentrations of ruxolitinib for 24 h. Cell lysates were immunoblotted with specific antibodies shown. GAPDH was used as loading control. (B) Transduced BaF3 cells were treated with increasing concentrations of ruxolitinib for 48 h. Cell proliferation was determined by CCK-8; K562 cells were used as negative control. Results represent the mean ± s.d. of 3 independent experiments.